Source: International Congress 2015 – Asthma mechanisms and management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Gail Gauvreau (Hamilton, Canada), Gail M. Gauvreau, Louis-Philippe Boulet, Richard Leigh, Donald W. Cockcroft, Beth E. Davis, Irvin Mayers, J. Mark FitzGerald, Barbro Dahlen, R.M. Watson, Joanne Milot, Veronica Swystun, Linda Hui, Ann-Sofie Lantz, Miranda Bowen, Jonathan Arm, Suzzane Maahs, Karin Meiser, Philip Lowe, Andrej Skerjanec, Christopher Carlsten, Karin Strandberg, Kieran J. Killian, Michele Laviolette, Anton Drollmann, Paul M. O’Byrne. QGE031 (ligelizumab) is more effective than omalizumab and placebo in inhibiting allergen-induced early asthmatic response: Results from a predictive modeling study. Eur Respir J 2015; 46: Suppl. 59, 5091

Member's Comments

No comment yet.

Related content which might interest you: Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 LATE-BREAKING ABSTRACT: Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting the allergen-induced early asthmatic response Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014 A PKPD mathematical model to determine efficacy of multiple doses of QGE031 (ligelizumab) vs. omalizumab and placebo in inhibiting skin responses in atopic asthmatics Source: International Congress 2015 – Asthma mechanisms and management Year: 2015 P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016 Interim analysis of a prospective study investigating oral corticosteroid (OCS) use in omalizumab treated severe allergic asthma patients: APEX II study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 LATE-BREAKING ABSTRACT: A phase 2 study of benralizumab on exacerbations, lung function, and asthma control in adults with uncontrolled eosinophilic asthma Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014 Omalizumab add-on therapy reduces exacerbations among responders: A pooled NNT analysis from 5 phase 3 studies Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Lung function response to omalizumab in severe allergic asthma patients in UK clinical practice: APEX II study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Evaluating omalizumab persistency of response after long-term therapy (XPORT) Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Effect of baseline eosinophil count on response to CYT003-QbG10 in patients with persistent allergic asthma Source: Annual Congress 2013 –Studies of asthma in man Year: 2013 Omalizumab in allergic eosinophilic asthma and lung eosinophil numbers: A 78-week randomized controlled trial Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Safety profile and pharmacokinetics of SB010, an inhaled GATA-3-specific DNAzyme, in phase I clinical trials in healthy and asthmatic subjects Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015 LATE-BREAKING ABSTRACT: Effects of a dual CysLT1/2 antagonist, ONO-6950, on allergen-induced airway responses in subjects with mild allergic asthma. Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 The clinical and genetic factors for predicting the response to inhaled corticosteroids Source: International Congress 2014 – Biomarkers of asthma and clinical immunology Year: 2014 Lung specific induction of Wnt-1 has a prophylactic and therapeutic effect on the development of an allergic airway disease Source: Annual Congress 2013 –Murine models of lung immunology Year: 2013 Combined therapy of asthma and allergic rhinitis Source: Annual Congress 2013 –Treatment of asthma Year: 2013 First clinical trial of a new IgE-adsorber in allergic asthma Source: International Congress 2015 – Novel mechanisms and treatments in allergy and asthma Year: 2015 Subcutaneous allergen specific immunotherapy and immunological response in patients with bronchial asthma and allergic rhinitis in India Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016